Form D · Biotechnology

ApoGen Biotechnologies, Inc.

Seattle, WA · CIK 0001691479

Offering snapshot reported Aug 24, 2018 · SEC filing

Reported sold: $7.57M
Investors reported: 24
Minimum accepted: $0
First sale: Nov 23, 2016

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$3,815,892 → $7,565,892
Reported investors23 → 24

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Aug 24, 2018	Amendment	$7,565,892	$3,750,000vs Dec 8, 2016	24	SEC filing
Dec 8, 2016	Initial	$3,815,892	No comparison	23	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-275911

Source: Form D, filed Aug 24, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Johnston Erwin	Director
M. Johnston Erwin	Director
Steve Gillis	Director
Keno Gutierrez	Director
Ian A.W. Howes	Executive
Thong Le	Director, Executive
Joel Marcus	Director
David Mc Elligott	Executive
Lindsay Rayle	Executive
John Santini	Director
David Schubert	Executive
James Sullivan	Director
Asish Xavier	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1616 Eastlake Ave E. Suite 200
Seattle, WA, 98102